Latest News and Press Releases

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial, Securing Alignment with FDA and EMA

Avacta announced compelling new data in patients with salivary gland cancer enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000)

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative...

BBOT today announced that members of its leadership team will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference.

$2.7M NIH grant evaluates TRE-515 with KRAS inhibitors in lung cancer, boosting Trethera’s FDA Fast Track pipeline with a novel approach to resistance

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies,...

EVOLVE104, a First-in-Class CD2 Costimulatory Trispecific T Cell Engager, is First Molecule from EVOLVE Platform to Enter the Clinic Trial Initiation Marks EvolveImmune’s Transition to Clinical-Stage...

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR BIORXIV QUI IDENTIFIE ET CARACTÉRISE UNE NOUVELLE MOLÉCULE SYNTHÉTIQUE, AB8939, COMME UN CANDIDAT MÉDICAMENT PROMETTEUR POUR LE...

PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE...

BetaGlue Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)